US 12,337,008 B2
Nutraceutical formulation for polycystic ovary syndrome
Ramesh Patodia, Mumbai (IN); and Sonal Chauhan, Mumbai (IN)
Filed by Ramesh Patodia, Mumbai (IN); and Sonal Chauhan, Mumbai (IN)
Filed on Nov. 16, 2021, as Appl. No. 17/527,581.
Application 17/527,581 is a continuation in part of application No. PCT/IN2020/000019, filed on Sep. 16, 2020.
Claims priority of application No. 201921037938 (IN), filed on Sep. 20, 2019.
Prior Publication US 2022/0072018 A1, Mar. 10, 2022
Int. Cl. A61K 31/7004 (2006.01); A23L 33/00 (2016.01); A23L 33/125 (2016.01); A23L 33/155 (2016.01); A23L 33/16 (2016.01); A23L 33/175 (2016.01); A23L 33/185 (2016.01); A23L 33/22 (2016.01); A61K 31/07 (2006.01); A61K 31/197 (2006.01); A61K 31/198 (2006.01); A61K 31/375 (2006.01); A61K 31/4188 (2006.01); A61K 31/455 (2006.01); A61K 31/51 (2006.01); A61K 31/519 (2006.01); A61K 31/525 (2006.01); A61K 31/555 (2006.01); A61K 31/59 (2006.01); A61K 31/675 (2006.01); A61K 31/733 (2006.01); A61K 33/04 (2006.01); A61K 33/06 (2006.01); A61K 33/10 (2006.01); A61K 33/14 (2006.01); A61K 33/18 (2006.01); A61K 33/26 (2006.01); A61K 33/30 (2006.01); A61K 33/32 (2006.01); A61K 38/16 (2006.01); A61P 5/28 (2006.01)
CPC A61K 31/7004 (2013.01) [A23L 33/125 (2016.08); A23L 33/155 (2016.08); A23L 33/16 (2016.08); A23L 33/175 (2016.08); A23L 33/185 (2016.08); A23L 33/22 (2016.08); A23L 33/40 (2016.08); A61K 31/07 (2013.01); A61K 31/197 (2013.01); A61K 31/198 (2013.01); A61K 31/375 (2013.01); A61K 31/4188 (2013.01); A61K 31/455 (2013.01); A61K 31/51 (2013.01); A61K 31/519 (2013.01); A61K 31/525 (2013.01); A61K 31/555 (2013.01); A61K 31/59 (2013.01); A61K 31/675 (2013.01); A61K 31/733 (2013.01); A61K 33/04 (2013.01); A61K 33/06 (2013.01); A61K 33/10 (2013.01); A61K 33/14 (2013.01); A61K 33/18 (2013.01); A61K 33/26 (2013.01); A61K 33/30 (2013.01); A61K 33/32 (2013.01); A61K 38/168 (2013.01); A61P 5/28 (2018.01); A23V 2002/00 (2013.01)] 4 Claims
 
1. A method of treating polycystic ovarian syndrome comprising administering 20 grams of a nutraceutical composition twice a day for two months to a subject in need thereof,
wherein the nutraceutical composition comprises a protein of plant origin, and an inositol, and wherein about 20 grams of the nutraceutical composition comprises:
about 8.8 grams of a combination of pea protein and rice protein,
about 7.6 grams of dietary fiber,
about 2 grams of myo-inositol;
about 0.05 grams of D-chiro inositol;
about 1.3 grams of inulin;
about 40 mg of Vitamin C;
about 40 mg of Calcium Carbonate;
about 40 mg of Magnesium Sulfate;
about 30 mg of Zinc Sulfate;
about 15 mg of Vit B5;
about 10 mg of sodium chloride;
about 10 mg of potassium chloride;
about 2.2 mg of Vit. B3;
about 1.6 mg of Vit B2;
about 0.6 mg of manganese sulfate;
about 0.2 mg of folic acid;
about 0.02 mg of Vitamin A;
about 40 mg of sodium selenite;
about 30 mg of biotin;
about 2 mcg of chromium picolinate;
about 2 mcg of potassium iodide;
about 1 mcg of Vit. B12;
about 0.85 mcg of L-glutamine;
about 0.71 mcg of L-Taurine;
about 0.56 mcg of L-lysine;
about 400 I.U. of Vitamin D,
and
wherein a symptom of poly cystic ovarian syndrome is selected from the group consisting of irregular or missing menstrual cycle, infertility, excess body or facial hair growth, thinning of hair on the scalp, weight gain around the waist, skin tags, skin darkening, appearance of acne, and combinations thereof.